|
显示项目 747886-747895 / 2349007 (共234901页)
<< < 74784 74785 74786 74787 74788 74789 74790 74791 74792 74793 > >>
每页显示[10|25|50]项目
| 正修科技大學 |
2009 |
Secu Tech Expo 2009 台北國際安全博覽會
|
謝隆斌 |
| 臺大學術典藏 |
2021-10-28T07:11:17Z |
Secukinumab 2-weekly vs. 4-weekly dosing in plaque-type psoriasis
|
TSEN-FANG TSAI |
| 國立臺灣大學 |
2016 |
Secukinumab delivers greater improvement in health-related quality of life compared to ustekinumab in subjects with moderate to severe plaque psoriasis: 16-week data from the CLEAR study
|
Rubel, D.; Thaci, D.; Blauvelt, A.; Reich, K.; Tsai, T. F.; Vanaclocha, F.; Kingo, K.; Ziv, M.; Pinter, A.; Hugot, S.; You, R.; Augustin, M.; Milutinovic, M.; 蔡呈芳 |
| 國立臺灣大學 |
2015 |
Secukinumab demonstrates an acceptable safety profile in moderate to severe plaque psoriasis: Pooled analysis of 10 phase 2/3 studies
|
Griffiths, Christopher; Reich, Kristian; Leonard, Craig; Blauvelt, Andrew; Mehta, Nehal; Tsai, Tsen-Fang; Gong, Yankun; Huang, Jiaqing; Fox, Todd; 蔡呈芳 |
| 國立臺灣大學 |
2016 |
Secukinumab demonstrates an acceptable safety profile in moderate to severe plaque psoriasis: Pooled analysis of 10 phase 2/3 studies
|
Foley, P.; Griffiths, C.; Reich, K.; Leonardi, C. L.; Blauvelt, A.; Mehta, N. N.; Tsai, T. F.; Gong, Y.; Papavassilis, C.; Huang, J.; Fox, T.; van de Kerkhof, P.; 蔡呈芳 |
| 臺大學術典藏 |
2019-09-16T09:25:16Z |
Secukinumab demonstrates superior efficacy and a faster response in clearing skin in Asian subjects with moderate to severe plaque psoriasis compared with ustekinumab: Subgroup analysis from the CLEAR study
|
Dee, Cathleen Michelle A.;Lee, Joo Heung;Guana, Adriana;Lee, Seung Chul;Huang, Yu Huei;Lee, Min Geol;Aw, Derrick Chen Wee;Bao, Weibin;Kim, Tae Gyun;TSEN-FANG TSAI; TSEN-FANG TSAI; Kim, Tae Gyun; Bao, Weibin; Aw, Derrick Chen Wee; Lee, Min Geol; Huang, Yu Huei; Lee, Seung Chul; Guana, Adriana; Lee, Joo Heung; Dee, Cathleen Michelle A. |
| 臺大學術典藏 |
2020-10-22T07:27:41Z |
Secukinumab demonstrates superior efficacy and a faster response in clearing skin in Asian subjects with moderate to severe plaque psoriasis compared with ustekinumab: Subgroup analysis from the CLEAR study
|
Dee C.M.A.; Guana A.; TSEN-FANG TSAI; Bao W.; Aw D.C.-W.; Kim T.-G.; Lee S.-C.; Lee J.-H.; Huang Y.-H.; Lee M.-G. |
| 中山醫學大學 |
2020 |
Secukinumab Demonstrates Sustained Efficacy and Safety in a Taiwanese Subpopulation With Active Ankylosing Spondylitis: Four-Year Results From a Phase 3 Study, MEASURE 1
|
Tseng, JC; Wei, JCC; Deodhar, A; Martin, R; Porter, B; McCreddin, S; Talloczy, Z |
| 臺大學術典藏 |
2019 |
Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: Results from the CLEAR study
|
Tha?I D.;Puig L.;Reich K.;Tsen-Fang Tsai;Tyring S.;Kingo K.;Ziv M.;Pinter A.;Vender R.;Lacombe A.;Xia S.;Bhosekar V.;Gilloteau I.;Guana A.;Blauvelt A.; Tha?i D.; Puig L.; Reich K.; TSEN-FANG TSAI; Tyring S.; Kingo K.; Ziv M.; Pinter A.; Vender R.; Lacombe A.; Xia S.; Bhosekar V.; Gilloteau I.; Guana A.; Blauvelt A. |
| 國立臺灣大學 |
2015 |
Secukinumab efficacy and safety in Asian subjects with moderate to severe plaque psoriasis: Pooled analysis from the FIXTURE and ERASURE phase III clinical studies
|
Lee, Jeung-Hoon; Morita, Akimichi; Tsai, Tsen-Fang; Zheng, Eugene; Ko, Luke; Fox, Todd; Langley, Richard; 蔡呈芳 |
显示项目 747886-747895 / 2349007 (共234901页)
<< < 74784 74785 74786 74787 74788 74789 74790 74791 74792 74793 > >>
每页显示[10|25|50]项目
|
